A study of AZD2962, an IRAK4 inhibitor (IRAK4 [a body protein] blocker), in Participants with Haematologic Neoplasms (Blood cancers)

Trial Identifier: D7770C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: November 2025
Primary Completion Date: October 2028
Study Completion Date: October 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Heidelberg, AU, 3084
AU Melbourne, AU, 3000
ES Barcelona, ES, 08035
ES Madrid, ES, 28033
ES Madrid, ES, 28027
ES Pamplona, ES, 31008
ES Salamanca, ES, 37007
ES Valencia, ES, 46026
GB London, GB, W1T 7HA
GB London, GB, SE5 9RS
GB Manchester, GB, M20 4BX
JP Shinagawa-ku, JP, 141-0022
JP Yoshida-gun, JP, 910-1193
TW Kaohsiung, TW, 83301
TW Tainan City, TW, 70403
TW Taipei, TW, 100
US, FL Miami, FL, US, 33136
US, FL Tampa, FL, US, 33612
US, Texas Houston, Texas, US, 77030